Molecular determinants of clinical outcomes for anaplastic lymphoma kinase –positive non-small cell lung cancer in Chinese patients: A retrospective study

Anaplastic lymphoma kinase (ALK) rearrangement is a unique molecular subtype of non-small cell lung cancer (NSCLC) that was first discovered in 2007 [1]. Most patients with this rearrangement that are diagnosed with adenocarcinoma are, on average, 10 years younger than patients with mutated EGFR and have never smoked or had a light smoking history [2]. ALK tyrosine kinase inhibitors (TKIs) are associated with a substantial improvement in patient survival and have been used as the first-line treatment [3].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Original Article Source Type: research